Pramipexole in Patients with Early Parkinsonʼs Disease

Hubble, Jean; Cutler, N.R.; Sramek, J.J.; Friedman, Jacqueline; Goetz, Christopher G.; Ranhosky, Alan; Korts, David C.; Elvin, Anders

doi:10.1097/00002826-199508000-00006

Cited by 129 publications

(51 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 Some studies did not find somnolence to be a common adverse event. 7,8 Other dopamine agonists can also cause somnolence. Ropinirole is a non-ergot dopamine agonist with a receptor binding profile similar to pramipexole.…”

Section: Discussionmentioning

confidence: 99%

Pramipexole-induced somnolence and episodes of daytime sleep

et al. 2000

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pramipexole-induced somnolence and episodes of daytime sleep

et al. 2000

View full text Add to dashboard Cite

“…Considering that OH can occur also as a complication of antiparkinsonian therapy, in the last decades many studies have been performed to test cardiovascular effects of different DAs on PD patients. Ergot DA, acting on both D1 and D2 dopamine receptors, induced hypotension probably by decreasing noradrenergic tone [5,6], whereas non-ergot DA seemed to be less active on the cardiovascular system, probably because of selective binding to D2 dopamine receptors [24,25,26]. Nevertheless, acute OH has been reported after starting non-ergot DA therapy [27], and asymptomatic OH has also been largely noted as a common adverse event of non-ergot DA long-term treatment or prolonged-release formulations [28,29,30].…”

Section: Discussionmentioning

confidence: 99%

The Impact of Rotigotine on Cardiovascular Autonomic Function in Early Parkinson’s Disease

et al. 2012

View full text Add to dashboard Cite

Dysautonomia can occur in early stages of Parkinson’s disease (PD) influencing tolerance to dopaminergic therapies. Rotigotine, a non-ergot dopamine agonist, has recently been developed as an effective alternative antiparkinsonian drug, but its influence on the autonomic nervous system was not investigated. Twenty subjects out of 34 consecutive de novo PD patients were submitted to full assessment of cardiovascular autonomic function before and after reaching a stable rotigotine regimen [6 mg/24 h (n = 3) or 8 mg/24 h (n = 17)]. Patients reached significant clinical improvement (–27% on the Unified Parkinson’s Disease Rating Scale part III) and did not show significant differences in cardiovascular tests compared to baseline data. However, an unexpected trend towards increasing systolic blood pressure after head-up tilt test was detected. Our study demonstrates that rotigotine does not influence cardiovascular autonomic responses in early de novo PD patients. Consequently, it may represent a well-tolerated and efficacious therapeutic option in newly diagnosed PD subjects.

show abstract

“…One such analysis was performed by Etminan et al [35], who compared adverse effects of ropinirole and pramipexole using meta-analyses of placebo-controlled or L -dopa-controlled trials. In the analysis of placebo-controlled trials in early PD (which consisted of 3 ropinirole trials with mean doses of 15.5 [12], 7.4 [13, 14] and 5.3 mg/day [36] and 3 pramipexole trials with doses of ≤6 [11], 3.8 (mean) [10] and ≤4.5 mg/day [37]), ropinirole was associated with a higher risk of hypotension and somnolence relative to placebo than pramipexole, and pramipexole was associated with a higher risk of hallucinations relative to placebo than ropinirole. Interestingly, recent studies in advanced PD with a 24-hour formulation of ropinirole demonstrated less prominent side effects of hypotension and sedation relative to the short-acting ropinirole formulation [38].…”

Section: Treatment Of Motor Symptomsmentioning

confidence: 99%

Treatment of Early Parkinson’s Disease

et al. 2009

View full text Add to dashboard Cite

The management of early Parkinson’s disease (PD) involves the treatment of motor symptoms and, increasingly, non-motor symptoms. Given the fast pace of clinical research in PD, clinicians are faced with the challenge of integrating the latest findings into the ongoing care of individual PD patients. Part 1 of this 2-part article reviews motor symptom efficacy data for the newest PD treatment options, as well as for established therapies. Safety and tolerability data are also reviewed. Part 2 of the article reviews key findings relevant to the assessment of potential neuroprotective therapies and the treatment of non-motor symptoms.

show abstract

Pramipexole in Patients with Early Parkinsonʼs Disease

Cited by 129 publications

References 0 publications

Pramipexole-induced somnolence and episodes of daytime sleep

Pramipexole-induced somnolence and episodes of daytime sleep

The Impact of Rotigotine on Cardiovascular Autonomic Function in Early Parkinson’s Disease

Treatment of Early Parkinson’s Disease

Contact Info

Product

Resources

About